A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-809
DRUG: Placebo
DRUG: VX-770

Sponsor

Vertex Pharmaceuticals Incorporated